Table 1.
Patients’ baseline characteristics: overall and according to tumor subtype
| Population evaluated for TILs levels | Population evaluated for CD8, FOXP3, PD-L1 | |||||
|---|---|---|---|---|---|---|
| Overall n (%) |
TN n (%) |
HER2+ n (%) |
Overall n (%) |
TN n (%) |
HER2+ n (%) |
|
| Tot, n | 94 | 43 | 51 | 64 | 28 | 36 |
| Age at BC diagnosis, yrs. median (Q1–Q3) | 49 (42–57) | 51 (44–61) | 46 (39–53) | 51 (43–59) | 54 (45–63) | 47 (41–57) |
| Time to relapse, mos median (Q1–Q3) | 27 (15–43) | 19 (11–38) | 31 (19–60) | 27 (16–47) | 18 (11–34) | 31 (21–55) |
| Time from relapse to biopsy, mos median (Q1–Q3) | 0 (0–5) | 0 (0–2) | 0 (0–11) | 0 (0–6) | 0 (0–2) | 0 (0–15) |
| Histotype | ||||||
| Ductal | 81 (86) | 36 (84) | 43 (84) | 56 (88) | 22 (79) | 34 (94) |
| Lobular | 5 (5) | 1 (2) | 4 (8) | 2 (3) | 1 (4) | 1 (3) |
| Other | 8 (9) | 6 (14) | 2 (4) | 6 (9) | 5 (17) | 1 (3) |
| Grade | ||||||
| 1–2 | 13 (14) | 3 (7) | 10 (20) | 9 (14) | 2 (7) | 7 (19) |
| 3 | 78 (86%) | 39 (93) | 39 (80) | 54 (86) | 25 (83) | 29 (81) |
| HR status | ||||||
| HR+ | 37 (39) | 0 (0) | 37 (72) | 26 (41) | 0 (0) | 26 (72) |
| HR- | 57 (61%) | 43 (100) | 14 (28) | 38 (59) | 28 (100) | 10 (28) |
| Stage at diagnosis | ||||||
| I–II | 50 (55) | 27 (66 | 23 (46) | 33 (52) | 17 (63) | 16 (44) |
| III | 38 (42) | 13 (32) | 25 (50) | 27 (43) | 9 (33) | 18 (50) |
| IV | 3 (3) | 1 (2) | 2 (4) | 3 (5) | 1 (4) | 2 (6) |
| Type of recurrent BC sample | ||||||
| Locoregional relapse | 40 (43) | 23 (53) | 17 (33) | 25 (39) | 13 (46) | 12 (33) |
| Distant relapse | 54 (57) | 20 (47) | 34 (67) | 39 (61) | 15 (54) | 24 (67) |
| Organ/site of biopsy | ||||||
| Liver | 24 (25) | 5 (12) | 19 (37) | 15 (23) | 4 (14) | 11 (31) |
| Skin | 38 (40) | 21 (49) | 17 (33) | 26 (41) | 13 (47) | 13 (36) |
| Lung | 12 (13) | 7 (16) | 5 (10) | 8 (13) | 4 (14) | 4 (11) |
| CNS | 9 (10) | 4 (9) | 5 (10) | 9 (14) | 4 (14) | 5 (14) |
| Other | 11 (12) | 6 (14) | 5 (10) | 6 (9) | 3 (11) | 3 (8) |
| Neo/adjuvant chemotherapy | ||||||
| No | 13 (14) | 3 (7) | 10 (20) | 9 (14) | 3 (11) | 6 (17) |
| Yes | 81 (86) | 40 (93) | 41 (80) | 55 (86) | 25 (89) | 30 (83) |
| Neo/adjuvant trastuzumab | ||||||
| No | – | – | 21 (41) | – | – | 12 (33) |
| Yes | – | – | 30 (59) | – | – | 24 (67) |
| Pre-biopsy systemic treatment for MBC | ||||||
| No | 70 (74) | 36 (88) | 34 (67) | 46 (72) | 25 (89) | 21 (58) |
| Yes | 24 (26) | 7 (17) | 17 (33) | 18 (28) | 3 (11) | 15 (42) |
Abbreviations: TILs tumor-infiltrating lymphocytes, TN triple negative, HER2 human epidermal growth factor receptor-2, n number, tot total, BC breast cancer, yrs years, mos months, Q1 first quartile, Q3 third quartile, HR hormone receptor, CNS central nervous system, MBC metastatic breast cancer